Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Liabilities and Shareholders Equity (2023 - 2025)

CG Oncology's Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $791.6 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 4.87% year-over-year to $791.6 million; the TTM value through Dec 2025 reached $3.0 billion, up 20.42%, while the annual FY2025 figure was $791.6 million, 4.87% up from the prior year.
  • Liabilities and Shareholders Equity reached $791.6 million in Q4 2025 per CGON's latest filing, up from $729.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $791.6 million in Q4 2025 to a low of $199.3 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $622.3 million, with a median of $701.4 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 278.72% in 2024, then increased 4.87% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $199.3 million in 2023, then surged by 278.72% to $754.8 million in 2024, then rose by 4.87% to $791.6 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Liabilities and Shareholders Equity are $791.6 million (Q4 2025), $729.9 million (Q3 2025), and $701.4 million (Q2 2025).